Advertisement

Picture Berlin Partner Top News Noah Labs Raises $3m AI Telemonitoring 650x100px
Organisation › Details

Roivant (Group)

Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. In addition to VTAMA, Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (“FcRn”) in development across several IgG-mediated autoimmune indications, and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical stage molecules. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. *

 

Period Start 2017-08-11 existent
Product Industry BIOTECH
Person Person Gline, Matthew (Matt) (Roivant 202102 CEO of Roivant Sciences)
     
  Street 50 Broadway
7th Floor
  City SW1H 0DB London
  Tel +44-207-400-3347
    Address record changed: 2024-09-24
     
Basic data Employees E: 501 to 1,000 (2024-03-31)
  Currency USD
  Annual sales 124,795,000 (revenue, net, consolidated (2023/24) 2024-03-31)
  Profit 4,231,206,000 (2024-03-31)
  Cash 6,535,706,000 (2024-03-31)
     
    * Document for »About Section«: Organon & Co.. (9/18/24). "Press Release: Organon to Acquire Dermavant including Its Innovative Dermatologic Therapy, Vtama (tapinarof) Cream, 1%". Jersey City, NJ.
     
   
Record changed: 2024-09-28

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for Roivant (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x300px




» top